Pain syndrome in rheumatology
https://doi.org/10.21518/2079-701X-2013-12-113-117
Abstract
About the Authors
N. А. ShostakRussian Federation
N. G. Pravdyuk
Russian Federation
A. A. Klimenko
Russian Federation
A. A. Kondrashov
Russian Federation
References
1. Алексеева Л.И., Зайцева Е.М. Субхондральная кость при остеоартрозе: новые возможности терапии. РМЖ, 2004;12(20):1133-1136.
2. Павлова В.Н., Павлов ГГ., Шостак Н.А., Слуцкий Л.И. Сустав: морфология, клиника, диагностика, лечение. М.: ООО «Издательство «Медицинское информационное агентство», 2011.
3. Ревматология: учеб. пособие / под ред. Н.А. Шостак М.: ГЭОТАР-Медиа, 2012.
4. Altman R, Asch E, Bloch D. et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum.,1986;29(8):1039-1049.
5. Altman R, Alarcon G, Appelrouth D. et al. The American College of Reumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum, 1991;34:505-514.
6. Dinesh Khanna, John D. Fitzgerald, Puja P. Khanna et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care & Research, 64(10) October 2012:1431-1446.
7. Насонова В.А. Вольтарен (диклофенак натрия) в ревматологии в начале XXI века. РМЖ, 2004;12(6):1380-1385.
8. Solomon DH, Glynn RJ, Rothman KJ. et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum, (Arthritis Care Res), 2008;59:1097-104.
9. Schwartz JI, Van Hecken A, De Lepeleire I. et al. Comparative inhibitory activity of rofecoxib (MK-0966), meloxicam, diclofenac, ibuprofen and naproxen on COX-2 VS COX-1 in healthy female volunteers. Poster EULAR 1999. Ann. Rheum. Dis, 1998;57:206.
10. McKenna F, Borenstein D, Wendt H. et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand. J. Rheumatol., 2001;30 (1):11-18.
11. Cannon GW, Caldwell JR, Holt P. et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum, 2000;43 (5):978-987.
12. Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol., 2003;15:173-178.
13. Biaco F, Guitian R, Moreno I. et al. NSAIDs effect on COX-1 and COX-2 activity in human articular chondrocytes. Arthr. Rheum., 1997;40:88.
Review
For citations:
Shostak NА, Pravdyuk NG, Klimenko AA, Kondrashov AA. Pain syndrome in rheumatology. Meditsinskiy sovet = Medical Council. 2013;(12):113-117. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-113-117